螺内酯治疗心力衰竭的价值

目的观察心力衰竭常规血管紧张素转换酶抑制剂(ACEI)治疗后血浆血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)水平变化,探讨加用螺内酯治疗对心力衰竭预后的影响。方法93例慢性心力衰竭患者随机分为两组。ACEI加螺内酯(螺内酯组)和不加螺内酯(对照组),采用放射免疫方法测定ACEI治疗前、治疗6个月时血浆肾素(PRA)、AngⅡ、ALD的水平,观察治疗前后PRA、AngⅡ、ALD的变化。以6分钟步行距离为客观指标,比较两组步行距离的改变,借以评价心功能改善的程度。结果①观察组治疗6个月后血浆ALD水平较治疗前明显升高[(205±30)pmol/L vs(148±60)pmol/L](P<0.01);对照组治疗6个月后血浆ALD水平较治疗前升高(170±68)pmol/L vs 144±63)pmol/L。但差异无统计学意义。②观察组治疗6个月时6分钟步行距离与治疗前比较明显增加[(420±163)m vs(338±118)m](P<0.01),对照组治疗6个月时步行距离有所增加[(380±112)m vs(346±106)m],但与治疗前比较,差异无统计学意义(P>0.05),两组治疗6个月后6分钟步行距离差异无统计学意义。结论①心力衰竭患者ACEI治疗后,不管是否加用螺内酯均可观察到醛固酮逃逸现象。加用螺内酯逃逸现象似乎更明显。这可能与螺内酯阻断醛固酮受体使血浆ALD游离浓度升高有关。②观察组6个月后6分钟步行距离明显增加。提示螺内酯改善心功能其机制可能与阻断ALD致Ⅰ、Ⅲ型胶原基因表达,使胶原合成增加促使心肌纤维化有关。     

内源性醛固酮与受体结合对肾性高血压大鼠血浆神经肽Y的调控

目的:观察在“一肾一夹”肾性高血压大鼠模型中,血浆神经肽Y含量的变化。方法:实验于2003-08/12在解放军总医院老年病研究所实验室完成。选用健康雄性Wistar大鼠21只,随机分为3组(n=7),分别为对照组和高血压组及螺内酯组。①分组干预:对照组:行假手术,10g/L盐水饮用,连续14d;高血压组:通过“一肾一夹”法(用直径0.2mm的银夹钳夹左侧肾动脉,使其部分狭窄,并切除右侧肾脏)复制肾性高血压大鼠模型,10g/L盐水饮用,连续14d;螺内酯组:造模同高血压组,螺内酯20mg/(kg·d)灌胃,连续14d。②14d后通过尾动脉法测量大鼠平均动脉压,取心脏组织称重后测量左心室质量/体质量比值。③用放射免疫的方法测定血浆神经肽Y、血管紧张素Ⅱ、醛固酮水平。结果:大鼠21只均进入结果分析。①平均动脉压水平:高血压组和螺内酯组均明显高于对照组[(187.14±28.56),(159.29±27.75),(127.14±8.59)mm Hg,1mm Hg=0.133kPa,P<0.05]。②心肌左心室质量/体质量比值:螺内酯组明显低于高血压组[(2.36±0.31),(3.02±0.64),P<0.05]。③血浆醛固酮水平:螺内酯组明显高于高血压组[(1.33±0.83),(0.54±0.26)ng/L,P<0.05]。④血浆神经肽Y水平:螺内酯组明显高于高血压组[(48222±33217),(5375±2916)ng/L,P<0.05]。结论:内源性醛固酮通过与受体结合可负性调控神经肽Y的分泌。     

冠心病患者血浆胆固醇与内皮素-1 C-反应蛋白及血小板可溶性P选择素相关性研究--附56例报告

目的 :了解冠状动脉粥样硬化性心脏病 (冠心病 )患者血浆胆固醇与内皮素 1、C反应蛋白 (C reactiveprotein ,CRP)及血小板可溶性P选择素 (solubleP selectin ,sP selectin)的关系。方法 :检测5 6例急性冠状动脉综合征 (acutecoronarysyndrome,ACS)、 2 3例慢性稳定型心绞痛 (chronicstableangina ,CSA)患者和对照组 10名正常人血浆总胆固醇、LDL C、内皮素 1、CRP和血小板sP selectin水平。结果 :ACS组血浆内皮素 1[(5 2± 10 )ng/L]、CRP水平 [(2 0± 9)mg/L]与CSA组 [(4 3± 4 )ng/L ,(13± 5 )mg/L]和正常对照组 [(36± 10 )ng/L ,(8± 2 )mg/L]比较差异均有统计学意义 ,均为P <0 0 1。血浆sP selectin水平ACS组 [(15 9± 5 8) μg/L]与CSA组 [(12 9± 1 9) μg/L]比较、CSA组与正常对照组[(6 7± 2 9) μg/L]比较 ,差异均有统计学意义 ,均为P <0 0 1。ACS组血浆总胆固醇、LDL C分别与内皮素 1、CRP、sP selectin呈正相关 [(r=0 2 9,P <0 0 5 ;r=0 5 6 ,P <0 0 1) ,(r=0 4 9,r =0 5 0 ,均为P<0 0 1) ,(r=0 30 ,P <0 0 5 ;r=0 5 4 ,P <0 0 1) ];CSA组血浆LDL C与CRP呈正相关 (r =0 4 7,P <0 0 5 )。结论 :ACS患者的血浆胆固醇可能有加重内皮功能障碍、刺激血管炎症反应和激活血     

白大衣高血压患者血浆肾素活性和血管紧张素Ⅱ及醛固酮水平变化及意义

目的探讨白大衣高血压(white-coat hypertension,WCH)患者血浆肾素活性(plasma renin activity,PRA),血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)、醛固酮(aldosterone,ALD)水平变化及WCH与肾素-血管紧张素-醛固酮系统的关系。方法 WCH患者150例为WCH组,轻中度原发性高血压患者161例为高血压组,同期体检健康者167例为对照组,比较3组诊室血压及24h平均血压;采用ELISA法检测3组血浆三酰甘油(triacylglycerol,TG)、总胆固醇(total cholesterol,TC)、高密度脂蛋白胆固醇(high density lipoprotein-cholesterol,HDL-C)、低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)水平;采用离子交换层析法检测3组糖化血红蛋白水平;采用化学发光免疫分析法检测3组卧位、立位血浆PRA及AngⅡ、ALD水平。结果WCH组诊室血压[(159±17)/(98±10)mm Hg]高于对照组[(123±16)/(78±12)mm Hg](P0.05),与高血压组[(154±11)/(99±10)mm Hg]比较差异无统计学意义(P0.05);WCH组24h平均血压[(119±20)/(78±10)mm Hg]低于高血压组[(138±10)/(86±12)mm Hg](P0.05),与对照组[(115±16)/(76±11)mm Hg]比较差异无统计学意义(P0.05);3组血浆TG、TC、HDL-C、LDL-C、糖化血红蛋白水平比较差异均无统计学意义(P0.05);WCH组血浆PRA、AngⅡ、ALD水平[立位:(3.70±2.36)ng/(mL·h)、(87.89±40.86)ng/L、(325.49±124.56)ng/L,卧位:(3.08±2.21)ng/(mL·h)、(85.57±42.81)ng/L、(295.69±138.47)ng/L]均高于高血压组[立位:(2.56±2.18)ng/(mL·h)、(72.12±17.16)ng/L、(299.44±111.23)ng/L,卧位:(2.25±2.02)ng/(mL·h)、(73.68±19.08)ng/L、(279.57±121.68)ng/L]和对照组[立位:(1.87±1.37)ng/(mL·h)、(58.73±18.23)ng/L、(247.95±76.83)ng/L;卧位:(1.79±1.32)ng/(mL·h)、(59.68±20.43)ng/L、(251.57±77.69)ng/L],且高血压组高于对照组(P0.05)。结论 WCH患者血浆PRA及AngⅡ、ALD水平均增高,肾素-血管紧张素-醛固酮系统可能参与WCH发病机制的调节。     

不同血液净化方式对慢性肾功能衰竭尿毒症患者血管活性物质的影响

目的探讨高通量血液透析(high-flux hemodialysis,HFHD)和低通量血液透析(low-flux hemodialysis,LFHD)对慢性肾功能衰竭尿毒症患者血清内皮素-l(endothelin-l,ET-1)、血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)、一氧化氮(nitric oxide,NO)的影响及临床意义。方法40例行维持性血液透析治疗慢性肾功能衰竭尿毒症患者随机分为HFHD组和LFHD组各20例,尿毒症未行血液透析患者20例为非透析组,同期体检健康者20例为对照组。检测HFHD组和LFHD组透析治疗前及治疗3个月血清肌酐(serum creatinine,SCr)、ET-1、AngⅡ、NO水平,并与非透析组、对照组进行比较。结果 (1)HFHD组及LFHD组治疗前ET-1[(181.22±24.36)、(180.14±25.91)ng/L]、AngⅡ[(80.54±19.37)、(81.47±18.27)ng/L]、肌酐[(900.45±148.73)、(901.31±147.89)μmol/L]以及非透析组以上指标[(130.55±33.27)ng/L、(66.51±13.11)ng/L、(904.71±156.25)μmol/L]均高于对照组[(55.24±13.72)ng/L、(40.77±21.42)ng/L、(75.54±16.27)μmol/L](P0.05),而NO水平[(178.41±21.39)、(179.42±22.51)、(172.49±29.18)μmol/L]均低于对照组[(263.55±12.33)μmol/L](P0.05);HFHD组及LFHD组治疗前ET-1、AngⅡ均高于非透析组,NO、肌酐与非透析组比较差异无统计学意义(P0.05);(2)透析治疗3个月,HFHD组ET-1[(116.13±10.09)ng/L]、AngⅡ[(50.49±20.07)ng/L]较治疗前下降(P0.05),NO[(179.14±19.05)μmol/L]较治疗前略有升高,但差异无统计学意义(P0.05);LFHD组治疗3个月后ET-1[(179.22±24.56)ng/L、AngⅡ(78.44±19.10)ng/L、NO(181.28±23.14)μmol/L]与治疗前比较差异无统计学意义(P0.05);HFHD组与LFHD组AngⅡ、ET-1水平比较差异有统计学意义(P0.05),NO、肌酐水平比较差异无统计学意义(P0.05)。结论 HFHD可提高肾功能衰竭尿毒症患者血管活性物质的清除率,改善其内皮细胞分泌功能,减少血管活性物质的释放。     

高血压患者ACE的基因多态性与血浆AngⅡ水平及其抑制药作用关系研究——附76例检测分析

目的:探讨高血压病患者血管紧张素转换酶(ACE)基因多态性与血管紧张素转换酶抑制药(A-CEI)对血浆中血管紧张素Ⅱ(AngⅡ)水平的影响.方法:高血压病或合并冠心病患者76例、健康对照组52名,应用PCR技术检测ACE基因及用放射免疫法检测AngⅡ水平.结果:高血压病患者血浆AngⅡ水平在ACE基因II,ID,DD型中分别是(102±43)ng/L,(104±44)ng/L,(106±43)ng/L;经ACEI治疗后分别下降为(76±28)ng/L,(76±28)ng/L,(78±29)ng/L.结论:ACE基因多态性与血浆AngⅡ水平无显著性差异(P＞0.05).     

内源性醛固酮与受体结合对肾性高血压大鼠血浆神经肽γ的调控

目的:观察在“一肾一夹”肾性高血压大鼠模型中,血浆神经肽Y含量的变化。方法:实验于2003-08/12在解放军总医院老年病研究所实验室完成。选用健康雄性Wistar大鼠21只,随机分为3组(n=7),分别为对照组和高血压组及螺内酯组。①分组干预:对照组:行假手术,10g/L盐水饮用,连续14d;高血压组:通过“一肾一夹”法(用直径0.2mm的银夹钳夹左侧肾动脉,使其部分狭窄,并切除右侧肾脏)复制肾性高血压大鼠模型,10g/L盐水饮用,连续14d;螺内酯组:造模同高血压组,螺内酯20mg/(kg·d)灌胃,连续14d。②14d后通过尾动脉法测量大鼠平均动脉压,取心脏组织称重后测量左心室质量/体质量比值。③用放射免疫的方法测定血浆神经肽Y、血管紧张素Ⅱ、醛固酮水平。结果:大鼠21只均进入结果分析。①平均动脉压水平:高血压组和螺内酯组均明显高于对照组[(187.14±28.56),(159.29±27.75),(127.14±8.59)mm Hg,1mm Hg=0.133kPa,P<0.05]。②心肌左心室质量/体质量比值:螺内酯组明显低于高血压组[(2.36±0.31),(3.02±0.64),P<0.05]。③血浆醛固酮水平:螺内酯组明显高于高血压组[(1.33±0.83),(0.54±0.26)ng/L,P<0.05]。④血浆神经肽Y水平:螺内酯组明显高于高血压组[(48222±33217),(5375±2916)ng/L,P<0.05]。结论:内源性醛固酮通过与受体结合可负性调控神经肽Y的分泌。     

高压氧对高血压脑出血患者血浆凝血酶水平的影响

目的 观察高压氧(HBO)治疗高血压脑出血患者的疗效及对患者血浆凝血酶水平的影响.方法 共选取高血压脑出血患者80例,采用随机数字表法将其分为对照组及治疗组.2组患者均给予常规内科处理,治疗组在此基础上辅以HBO治疗.分别于治疗前、治疗24 h、1周及2周后空腹抽取静脉血行血浆凝血酶测定;同时于发病24 h内、发病后第7天时及治疗1周、2周后进行神经功能缺损评分.结果 治疗前及治疗24 h时,发现治疗组血浆凝血酶水平[(10.53±2.45) ng/ml,(12.76±2.27) ng/ml]与对照组血浆凝血酶水平[(10.61±2.27) ng/ml,(12.82 ±2.08) ng/ml]组间差异均无统计学意义(P＞0.05);经HBO治疗1周及2周后,发现治疗组血浆凝血酶水平[(10.22±1.87) ng/ml,(8.58±2.29) ng/ml]均显著低于对照组[(12.02±1.84) ng/ml,(10.00±1.78) ng/ml],组间差异均具有统计学意义(均P＜0.05).在发病24 h内及发病后第7天时,发现治疗组神经功能缺损评分[(18.83±6.50)分,(17.40±6.41)分]与对照组神经功能缺损评分[(18.88 ±6.13)分,(17.65 ±5.97)分]组间差异均无统计学意义(P＞0.05);经HBO治疗1周及2周后,发现治疗组神经功能缺损评分[(12.08 ±4.07)分,(9.65 ±3.68)分]均显著低于对照组[(16.50±5.57)分,(14.15±4.94)分],组间差异均具有统计学意义(P＜0.05).结论 HBO治疗能显著促进高血压脑出血患者神经功能恢复,其治疗机制可能与HBO降低血浆凝血酶水平有关.     

急性心肌梗死患者血浆脑钠素峰值浓度的变化与预后的关系

目的探讨血浆脑钠素(BNP)峰值浓度的变化与急性心肌梗死(AMI)预后的关系。方法用放射免疫法测定78例AMI患者入院即刻、6、12、18、24小时,第3、5、7天血浆BNP浓度,经住院期间及出院后平均12个月的随访,观察早期再灌注组与非早期再灌注组患者的血浆BNP峰值浓度的差异,以及心血管事件发生组与未发生组患者的血浆BNP峰值浓度的差异。结果AMI后血浆BNP第一峰值浓度(386.3±114.0)ng/L和第二峰值浓度(296.5±96.2)ng/L均呈显著升高,明显高于正常对照组(52.6±27.1)ng/L,两组比较差异有统计学意义(P<0.01);早期再灌注可明显降低AMI患者BNP第二峰值浓度[(301±97.7)ng/L对(176.4±105.6)ng/L(P<0.01)];发生心血管事件的患者血浆BNP第一、第二峰值浓度明显高于未发生组[(406.5±98.2)ng/L,(348.4±99.3)ng/L对(341.1±104.3)ng/L,(224.9±92.5)ng/L(P<0.01)]。结论BNP可作为AMI后评估预后的血浆标记物之一。积极的早期再灌注治疗有助于血浆脑钠素峰值浓度的降低和AMI预后的改善。     

伊贝沙坦对高血压患者心肌纤维化的影响--附48例报告

目的:探讨血管紧张素Ⅱ受体拮抗药伊贝沙坦对高血压患者心肌纤维化的影响.方法:48例高血压患者服用伊贝沙坦150～300mg,每日1次,疗程24周.治疗前后测定血清Ⅲ型前胶原氨基末端肽(aminoterminal propeptide of type Ⅲ procollagen,PⅢP)、转化生长因子β1(transforming growth factorβ1,TGF-β1)及血浆血管紧张素Ⅱ(angiotensinⅡ,AngⅡ),并与正常对照组(30名)比较.结果:治疗前高血压组PⅢP[(7.3±1.9)μg/L]、TGF-β1[(25.6±3.0)μg/L]及AngⅡ浓度[(67±11)ng/L]均高于正常对照组[(4.5±1.2)μg/L、(10.4±2.1)μg/L、(41±11)ng/L],均为P＜0.05;伊贝沙坦治疗24周后PⅢP[(5.0±1.6)μg/L]、TGF-β1[(15.8±2.8)μg/L]浓度均比治疗前明显下降,均为P＜0.05;AngⅡ[(70±13)ng/L]则与治疗前比较无明显变化,P＞0.05.结论:伊贝沙坦能显著降低高血压患者血清中的胶原含量,降低TGF-β1浓度,因而有可能会减轻心肌纤维化.     

艾司洛尔和硝普钠控制性降压对鼻内窦手术病人血利尿钠肽的影响

目的研究控制性降压对鼻内窦术病人血浆心房利尿钠肽（ANP）和脑利尿钠肽（BNP）水平的影响。方法选择45例无心血管疾病拟实行鼻内窦术病人随机分成三组，每组15例即控制性降压艾洛尔组和硝普钠组平均动脉压（MAP）维持在50-55mmHg；对照组平均动脉压维持在70～80mmHg。在下列各时点测定血ANP和BNP浓度：术前（T1）、手术结束时（T2）、2h（T3）、24h（T4）、48h（T5）。结果术前ANP和BNP水平均在正常范围并且三组水平均相似，与对照组（ANP5．31±2．32ug／ml；BNP13．26±8．98ug／ml，P〈0．01）相比艾司洛尔组（ANP2．46±0．75ug／ml；BNP4．34±3．06ug／m1）和硝普钠组（ANP2．48±0．92ug／ml；BNP4．49±3．21ug／m1）T2，T3时点ANP和BNP浓度均下降，并且失血量减少和手术时间缩短。结论控制性降压减少心血管健康病人利尿钠肽的释放。这种作用是通过降低全身阻力和灌注压引起心室充盈压下降引起而实现。     

A Look at Narcotic and Nonnarcotic Analgesics

At a time when drug abuse is a matter of general concern, the logic behind the choice of an analgesic is very important. Aside from addiction potential, all the narcotics share side effects that mean trouble even when addiction is not a worry, as in terminal cancer. Some analgesics with specific properties, far from being abused, are underused.     

Analytical correlation between plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in patients presenting with dyspnea

OBJECTIVES: We examined the analytical correlation N-terminal pro-brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP). DESIGN AND METHODS: Electrochemiluminescence and fluorescence immunoassays were used to measure NT-proBNP and BNP levels, respectively. RESULTS: The analytical correlation was satisfactory using the equation: NT-proBNP = 8.56 x BNP + 91.7 and a correlation r = 0.85. The correlation was not influenced by age, gender and BMI of patients. CONCLUSIONS: We conclude that NT-proBNP correlates with BNP.     

Marked elevations in N-terminal brain natriuretic peptide levels in septic shock

Introduction  

N-terminal pro brain natriuretic peptide (NT-proBNP) is a cardiac biomarker that has recently shown to be of diagnostic value in a diagnosis of decompensated heart failure, acute coronary syndromes and other conditions resulting in myocardial stretch. We sought to study whether sepsis-induced myocardial dilation would result in an elevation of NT-proBNP.     

血浆N末端B型钠尿肽前体对重症患者预后的预测价值研究

目的 探讨入重症监护病房(ICU)时血浆N末端B型钠尿肽前体(NT-pro-BNP)水平是否是预测重症患者预后的独立因子.方法 采用前瞻性、单中心、观察性研究方法.选择6个月内入本院ICU＞18岁的120例患者,最终有88例患者符合试验要求.血浆NT-pro-BNP样本在进入ICU时收集;计算进入ICU后24 h内急性生理学与慢性健康状况评分系统Ⅱ(APACHE Ⅱ)的最差值;入ICU后28 d患者生存状态为预测终点.结果 入ICU 28 d死亡35例,病死率为39.8%.88例患者血浆NT-pro-BNP水平(ng/L)为1221.7(78.7～5 500.0),生存组明显低于死亡组[781.8(78.7～5 066.6)比2 774.5(166.8～5 500.0),P＜0.01].男性NT-pro-BNP水平(ng/L)高于女性[1 585.5(103.7～5 100.0)比794.5(78.7～5 500.0),P＜0.05];性别与NT-pro-BNP水平有相关性(r=-0.224,P＜0.05).进入ICU时重度感染患者NT-pro-BNP水平(ng/L)较其他患者更高[3 416.1(103.7～5 100.0)比883.4(78.7～5 500.0),P＜0.01];入ICU时是否存在重度感染与NT-pro-BNP水平有相关性(r=0.285,P＜0.01).NT-pro-BNP和APACHE Ⅱ评分的受试者工作特征曲线(ROC曲线)下面积分别为0.734[95%可信区间(95%CI)0.628～0.840]和0.747(95%CI0.637～0.858).Logistic回归分析显示:入ICU时NT-pro-BNP水平＞1 418 ng/L和APACHE Ⅱ评分均可作为28 d生存状态预测的独立因子[相对比值比(OR)5.235,95%CI 1.819～15.071;OR 1.105,95%CI1.819～15.071].以入ICU时NT-pro-BNP最佳临界值1 418 ng/L为分界点进行生存分析,高于此值者生存率比低于此值者低(x2=16.9,P＜0.01).结论 入ICU时血浆NT-pro-BNP＞1 418 ng/L和APACHE Ⅱ评分可作为重症患者短期生存状态的预测因子;NT-pro-BNP值可能用来诊断或者鉴别重度感染患者.

Abstract：

Objective To investigate whether plasma N-terminal pro-B-type natriuretic peptide (NT-pro-BNP)as measured at admission to intensive care unit(ICU)is an independent predictor of mortality in critically ill patients. Methods A prospective observational study of patients in ICU was conducted. One hundred and twenty patients aged＞18 years were included during a 6-month period. Among them 88 patients were enrolled for the study. Plasma NT-pro-BNP samples were obtained at admission to ICU. The acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ)score was calculated within 24hours after admission based on the worst values up to that point. The final evaluation was 28-day mortality.Results Thirty-five patients died within 28 days of ICU admission, the mortality was 39. 8%. In 88 patients, the mean plasma NT-pro-BNP levels(ng/L)were 1 221.7(78.7- 5 500.0), and that in survivor group was significantly lower than non-survivor group[781.8(78. 7 - 5 066. 6)vs. 2 774. 5(166.8 - 5 500.0), P＜0.01]. The mean NT-pro-BNP level(ng/L)in male patients was higher than that in females[1 585. 5(103.7 - 5 100. 0)vs. 794. 5(78. 7 - 5 500. 0), P＜0. 05]. There was correlation between gender and NT-pro-BNP levels(r=-0. 224, P＜0. 05). Patients admitted to the ICU because of a severe infection had higher levels of NT-pro-BNP(ng/L)compared with the rest of the cohorts[3 416.1(103. 7 -5 100.0)vs. 883. 4(78. 7 - 5 500. 0), P＜0.01]. There was correlation between severe infection at admission to ICU and NT-pro-BNP levels(r=0. 285, P＜0. 01). Areas under the receiver operating characteristic curves(ROC curves)of NT-pro-BNP and APACHE I score were 0. 734[95% confidence interval(95%CI)0. 628 - 0. 840]and 0. 747(95%CI 0. 637 - 0. 858), respectively. Logistic regression analysis showed that the NT-pro-BNP level ＞ 1 418 ng/L and the APACHE I score were independently associated with 28-day mortality[odds ratio(OR)5.235, 95%CI 1.819- 15.071; OR 1.105, 95%CI 1.819- 15.071]. WithI 418 ng/L of NT-pro-BNP as the cutoff value, survival rate was significantly lower in the patients with higher NT-pro-BNP level as compared with those with lower values at admission(x2= 16.9, P＜0. 01).Conclusion The ICU NT-pro-BNP level higher than 1 418 ng/L and APACHE Ⅱ score at admission are independent prognosis markers of early mortality. NT-pro-BNP might serve as a potent early diagnostic and prognostic marker in critically ill patients.     

Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction

Brain natriuretic peptide (BNP), NT-proBNP and NT-pro-atrial natriuretic peptide (NT-proANP) were measured in blood samples from 57 patients using immunoassays and immunoradiometric assays to evaluate the usefulness as diagnostic markers for the detection of heart failure. For the detection of impaired left ventricular ejection fraction (LVEF), receiver operating characteristic curves showed that BNP had the best diagnostic performance with an area under curve (AUC) of 0.75±0.06. However, NT-proBNP (AUC: 0.67±0.07) and NT-proANP (AUC: 0.69±0.08) showed no significant difference to BNP. In a further analysis for the detection of resting LVEF <40%, BNP again was the best marker with an AUC of 0.83±0.06. NT-proBNP showed only a slightly smaller AUC (0.79±0.07). The AUC for NT-proANP was significantly smaller (0.65±0.08) compared to BNP. Additionally, BNP and NT-proBNP correlated negatively with the resting LVEF (BNP: −0.472, p<0.001; NT-proBNP: −0.306, p=0.026), whereas NT-proANP showed no significant correlation. In summary, BNP was the best marker to detect patients with impaired LVEF compared to NT-proBNP and NT-proANP. However, NT-proBNP showed no significant differences to BNP and it is therefore a new promising alternative marker for the detection of left ventricular dysfunction.     

等张运动和抗阻运动对血浆利钠肽激素的影响

目的 :比较等张运动和抗阻运动对血浆利钠肽激素的影响。方法 :8例健康男性采用相同靶心率和相同运动时间 ,分别进行等张运动和交替抗阻运行 ,观察运动前后血浆利钠肽的应激变化。结果 :血浆心房利钠肽和脑利钠肽在等张运动后并行性显著增高 ,抗阻运动后增高不明显 ,但其分泌程度与两项乘积呈正相关。结论 :运动可以导致血浆利钠肽激素的增高 ,体内各激素水平之间存在着交互抑制的现象 ,两种运动形式均有利于提高冠状血管的贮备功能     

Variability of Nt-proANP and C-ANP

BACKGROUND: Natriuretic peptides are frequently measured in patients with chronic cardiac failure (CCF). We set out to compare the variability of atrial natriuretic peptide (C-ANP) and its precursor N-terminal pro-ANP (Nt-proANP) to decide which would be more suitable for routine use. METHODS: Ten males with compensated CCF (age range 62-76 years) were studied, with matched controls. Blood was withdrawn every 2 min for 90 min from a forearm vein, and plasma C-ANP and Nt-proANP were measured by radioimmunoassay. RESULTS: Levels were elevated in the patient group [C-ANP: median 268 (range 171-423) vs. 40 (28-56) ng L-1, P < 0.0002 Mann-Whitney U-test; Nt-proANP: 1955 (562-4451) vs. 621 (409-961) pmol L-1, P < 0.003]. A similar number of 'peaks' was observed in both groups with both peptides, about one every 10 min, and their relative height was similar in both groups. Variability was greater for C-ANP than for Nt-proANP in both patients [coefficient of variation of means 51 (range 36-70) vs. 3.6 (2.1-6.2)%, P < 0.01; sign test] and controls [65 (49-83) vs. 8.9 (4.7-13.5)%, P < 0.01]. CONCLUSION: Nt-proANP is less variable than C-ANP and hence more suited for diagnostic or prognostic use.     

AV nodal ablation and pacemaker implantation improves hemodynamic function in atrial fibrillation

In drug refractory and highly symptomatic atrial fibrillation (AF) patients, hemodynamic effects of AV node ablation and pacing therapy (APT) were evaluated. Thirty-eight patients with drug refractory and symptomatic AF, underwent APT in eight centers in Japan. The outcome of this therapy was assessed in terms of quality-of-life, cardiac performance measured by echocardiogram, and plasma ANP and BNP levels before and after APT. Quality-of-life assessed by self-administered semi-quantitative questionnaires: WHO QOL 26 (3.0 +/- 0.5 vs 3.4 +/- 0.6, P < 0.01) and the Symptom Checklist: Frequency Scale (1.6 +/- 0.6 vs 0.7 +/- 0.7, P < 0.01) and Severity Scale (1.3 +/- 0.4 vs 0.6 +/- 0.6, P < 0.01), improved significantly 6 months after APT. Ejection fraction (EF) by echocardiogram improved 1 week after APT (59.0% +/- 13.3% vs 63.3% +/- 11.6%, P = 0.02). Plasma ANP levels in the group of ANP > 40 pg/mL at enrollment significantly decreased 1 month later (P = 0.03), and plasma BNP levels in the group of BNP > 20 pg/mL at enrollment significantly decreased 1 month later (P < 0.01). In conclusion, APT has beneficial hemodynamic effects, and plasma BNP levels can predict the most optimal candidates for ablation and pacing therapy.     

利钾尿肽与心钠素摩尔比在心房纤颤时的作用

目的 :探讨利钾尿肽 (KP)及 KP与心钠素 (ANP)摩尔比在心房纤颤 (房颤 )时的意义。方法 :用放射免疫 (放免 )分析法测定 2 3例阵发房颤患者和 2 4例持续房颤患者血浆中 KP与 ANP的水平 ,并以正常人作为对照。结果 :房颤患者血浆中 KP与 ANP的水平明显高于对照组 (P均 <0 .0 1) ,阵发房颤患者血浆中 KP/ ANP摩尔比显著低于正常对照组 (P<0 .0 1) ;持续房颤患者血浆中 KP/ ANP摩尔比与正常对照组相似 (P>0 .0 5 )。结论 :KP含量与 ANP比例关系的变化在房颤发病中起一定的作用